We are delighted to announce that Dr Raza Ali will be joining the Institute as a new Junior Group Leader in early 2020.
Raza studied Medicine at Cardiff University, later specialising in Histopathology before joining the Caldas Group for his PhD as a Clinical Research Fellow. After completing his PhD, he was granted an NIHR Academic Clinical Lecturer position as the Department of Pathology before being awarded a CRUK Clinical Scientist Fellowship, where he worked on immune checkpoint programs to target immunotherapy in triple-negative breast cancer at the University of Zurich.
During his tenure as Junior Group Leader, Raza will model how the tumour-immune interaction changes over time in breast cancer. There is an urgent need to identify breast cancer patients who will benefit from immunotherapy, with current biomarkers unable to identify patients that will experience a long-term benefit and those likely to develop resistance in the short-term.
Raza will precisely map the key cellular players within the tumour-immune ecosystem to provide snapshots of disease progression. Translating these findings from state-of-the-art research into clinical-grade assays is an important goal, with the ultimate aim being to personalise immunotherapy and bring real benefit to patients in the clinic.
We look forward to welcoming Raza to the Institute.